stockrowEton Pharmaceuticals, Inc. (ETON) vs Xeris Biopharma Holdings, Inc. (XERS)
- Eton Pharmaceuticals, Inc. ETON 55.58 +17.88%
- Xeris Biopharma Holdings, Inc. XERS 14.50 +10.86%
Eton Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $2.4B against $1.4B — 1.8× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Eton Pharmaceuticals, Inc. trades at 26.8×. Eton Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 100.6% against 38.4%. Eton Pharmaceuticals, Inc. has the higher net margin (35.4% vs −1.76%) and the higher return on invested capital (46.8% vs 27.2%). Across the 20 metrics below, Eton Pharmaceuticals, Inc. leads on 12 and Xeris Biopharma Holdings, Inc. on 8.
Valuation
Profitability
| Metric | ETON | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 69.15% | 87.38% | 53.51% |
| Operating margin | 28.84% | 12.70% | 0.00% |
| Net margin | 35.35% | (1.76%) | (2.45%) |
| Free cash flow margin | 14.17% | 20.00% | 0.00% |
| Return on equity | 90.62% | (27.11%) | (0.80%) |
| Return on assets | 38.10% | (1.64%) | (1.67%) |
| Return on invested capital | 46.77% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack